

1	<p><b>Treatment &amp; Condition</b></p> <p>Canagliflozin in combination therapy for treating Type 2 Diabetes</p>
2	<p><b>Associated appraisal body &amp; Summary of ruling</b> <i>(to include indication, restrictions, other relevant information)</i></p> <p>NICE Technology Appraisal Guidance 315 (June 2014)</p> <p>NICE recommends Canagliflozin in combination for treating type 2 diabetes as follows:</p> <ul style="list-style-type: none"> <li>2.1 Canagliflozin in a dual therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if: <ul style="list-style-type: none"> <li>-a sulfonylurea is contraindicated or not tolerated or</li> <li>-the person is at significant risk of hypoglycaemia or its consequences.</li> </ul> </li> <li>2.2 Canagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in combination with: <ul style="list-style-type: none"> <li>-metformin and a sulfonylurea or</li> <li>-metformin and a thiazolidinedione.</li> </ul> </li> <li>2.3 Canagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option for treating type 2 diabetes.</li> <li>2.4 People currently receiving treatment initiated within the NHS with Canagliflozin that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.</li> </ul>
3	<p><b>Number of people in Northern Ireland expected to take up service/therapy</b> <i>(including new cases per year)</i></p> <p>The NICE Costing Template that accompanies TA315 estimates that 34,081 people in Northern Ireland would be eligible to receive this therapy.</p>
4	<p><b>Patient Access Scheme availability</b></p> <p>Not applicable</p>

<b>5</b>	<b>Costs</b> <i>(before PAS if applicable)</i>																				
<b>5.1</b>	<p><b>Drug cost per patient per annum (for new and prevalent cases)</b></p> <p>The list price is £39.20 for Canagliflozin 100mg (30 tablets) and £49.99 for Canagliflozin 300mg (30 tablets) (excluding VAT; 'British National Formulary' BNF June 2014).</p> <p>The recommended starting dosage of Canagliflozin is 100mg once daily, which can be increased to 300mg daily where this provides insufficient glycaemic control. The decision to escalate to the higher dosage is likely to be made in the first 6 to 12 months of treatment. Based on expert opinion in the NICE Costing Template it is estimated that 50% of patients will progress to the 300mg dose.</p> <p>The expected annual cost of Canagliflozin is £476.93 for the 100mg daily dosage and £608.21 for the 300mg daily dosage.</p>																				
<b>5.2</b>	<p><b>Infrastructure costs per patient per annum</b></p> <p>No additional infrastructure costs have been identified.</p>																				
<b>5.3</b>	<p><b>Current in year costs</b></p> <p>Assuming a steady uptake in the second half of 2014/15, estimated costs would be £90k. It is expected that costs will be incurred in primary care only.</p>																				
<b>5.4</b>	<p><b>Recurrent overall costs per annum</b> <i>(including additional costs)</i></p> <table border="1"> <thead> <tr> <th>Treatment</th> <th>Current practice</th> <th>Future practice</th> <th>Net impact</th> </tr> </thead> <tbody> <tr> <td>Dual therapy</td> <td>£2,433,866</td> <td>£2,632,549</td> <td>£198,683</td> </tr> <tr> <td>Triple Therapy</td> <td>£2,279,290</td> <td>£2,392,631</td> <td>£113,341</td> </tr> <tr> <td>Combination with insulin</td> <td>£1,467,297</td> <td>£1,536,555</td> <td>£69,259</td> </tr> <tr> <td><b>Total</b></td> <td><b>£6,180,453</b></td> <td><b>£6,561,736</b></td> <td><b>£381,283</b></td> </tr> </tbody> </table> <p>The NICE costing template using standard assumptions estimates total recurrent costs as being £381k. It is expected that costs will be incurred in primary care only.</p>	Treatment	Current practice	Future practice	Net impact	Dual therapy	£2,433,866	£2,632,549	£198,683	Triple Therapy	£2,279,290	£2,392,631	£113,341	Combination with insulin	£1,467,297	£1,536,555	£69,259	<b>Total</b>	<b>£6,180,453</b>	<b>£6,561,736</b>	<b>£381,283</b>
Treatment	Current practice	Future practice	Net impact																		
Dual therapy	£2,433,866	£2,632,549	£198,683																		
Triple Therapy	£2,279,290	£2,392,631	£113,341																		
Combination with insulin	£1,467,297	£1,536,555	£69,259																		
<b>Total</b>	<b>£6,180,453</b>	<b>£6,561,736</b>	<b>£381,283</b>																		
<b>5.5</b>	<p><b>Opportunities for cost savings and how these will be secured</b></p> <p>As outlined above, the additional treatment costs for this cohort of patients with type 2 diabetes are estimated at £381k per annum. The cost of introducing canagliflozin in combination therapy has been offset to reflect any savings.</p>																				
<b>6</b>	<p><b>Expected implementation period</b></p> <p>Immediate implementation is expected.</p>																				

7	<p><b>Commissioning arrangements</b></p> <p>Canagliflozin is not a first or second line therapy and will not be a NI Formulary choice. Primary and secondary care will be notified of the place of this drug in therapy.</p>
8	<p><b>Monitoring arrangements</b></p> <p>Uptake of this drug in primary and secondary care will be monitored by HSCB Pharmacy and Medicines Management Team.</p> <p>Trusts must audit all new drugs for diabetes re compliance with NICE and NI formulary. Local commissioning groups will be expected to follow up with Trusts on an on-going basis to ensure compliance on these issues.</p>
9	<p><b>DHSSPS Legislative/Policy Caveats</b> <i>(NICE guidance only)</i></p> <p>This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.</p>